Company Overview
Company Type: Public Company
Website: www.ventripoint.com
Number of Employees: -
Ticker: VPT (TSXV)
Year Founded: 2004


Business Description
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patientâ€™s heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity of chemotherapy treatments for cancer, and Covid-19 related heart issues. The company was incorporated in 2005 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.1
Market Capitalization
29.0
TEV/Total Revenue
NM
EBITDA
(5.0)
Total Enterprise Value
26.1
TEV/EBITDA
NM
EBIT
(5.0)
Cash & ST Invst.
3.3
P/Diluted EPS Before Extra
NM
Net Income
(5.0)
Total Debt
0.4
Price/Tang BV
12.1x
Total Assets
3.9
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Adams, George 
Executive Chairman
Macanovic, Alvira 
CEO, President and VP of Operations, Regulatory Affairs & Quality Assurance
Jeon, Jimmy 
Chief Financial Officer
Katagiri, Hirotaka 
CTO &  Business Development Division Director
Naman, Jessica 
Director of Marketing
Graba, Jim 
Application Specialist & Chief Trainer
Hirson, Desmond 
Consultant

Key Board Members
Name
Title
Adams, George 
Executive Chairman
Schwartz, Samuel 
Chair of Business Advisory Committee
AuCoin, Randy 
Director
Fitzgerald, Fiona 
Director
Gatzoulis, Michael
Member of Scientific Advisory Board
Hodgkinson, Robert 
Independent Director
Krasuski, Richard
Member of Scientific Advisory Board
Lewin, Mark
Member of Scientific Advisory Board
MacNaught, Hugh 
Independent Director
Sahn, David
Member of Scientific Advisory Board
Skinner, Gregory 
Member of Board of Clinical Advisors
Solomon, Scott D. 
Member of Scientific Advisory Board


Primary Industry Classification
Health Care Equipment


Primary Office Location
18 Hook Avenue Unit 101 | Toronto, ON | M6P 1T4 | Canada
Phone: 416-848-4156   

Current and Pending Investors
YuTian Medical Investment Management Co. Ltd

Prior Investors
BluMont Capital Corporation

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.18
Market Cap (mm)
28.2
Open
 0.19
Shares Out. (mm)
156.8
Previous Close
 0.18
Float %
98.1%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(2.7)%
Dividend Yield %
-
Day High/Low
 0.19/ 0.18
Diluted EPS Excl. Extra Items
(0.03)
52 wk High/Low
 0.35/ 0.12
P/Diluted EPS Before Extra
NM
Volume (mm)
0.09
Avg 3M Dly Vlm (mm)
0.15
Beta 5Y
0.23


 
Delayed Quote** | Last Updated on Oct-10-2023 12:00 AM (GMT-5)
TSXV:VPT - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Luca Capital Inc.
As of September 18, 2007, Luca Capital Inc. was acquired by VentriPoint, Inc. in a reverse merger transaction. Luca Capital, Inc., a capital pool company, does not have significant operations. It intends to identify and evaluate companies, businesses, or assets with a view to complete a qualifying transaction. Luca Capital was co-founded by Danny D. Dalla-Longa and Al J. Kroontje. The company was incorporated in May 2005 and is headquartered in Calgary, Canada.

United States and Canada
Asset Management and Custody Banks
-
1.00
0.00
VentriPoint, Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-27-2021
Oct-20-2021
Public Offering
Target
VentriPoint Diagnostics Ltd. (TSXV:VPT)


7.00
Jan-28-2020
Sep-14-2020
Private Placement
Target
VentriPoint Diagnostics Ltd. (TSXV:VPT)
YuTian Medical Investment Management Co. Ltd

0.93
Aug-16-2019
Oct-02-2019
Private Placement
Target
VentriPoint Diagnostics Ltd. (TSXV:VPT)


0.53
Jan-09-2019
Jan-28-2019
Private Placement
Target
VentriPoint Diagnostics Ltd. (TSXV:VPT)


1.14
Aug-15-2018
Sep-14-2018
Private Placement
Target
VentriPoint Diagnostics Ltd. (TSXV:VPT)


0.78
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-04-2023
Executive Changes - CFO
VentriPoint Diagnostics Ltd. Announces Executive Changes
Sep-06-2023
Earnings Calls
VentriPoint Diagnostics Ltd., Q2 2023 Earnings Call, Sep 06, 2023
Aug-22-2023
Client Announcements
Ventripoint Welcomes Evelina London Children's Hospital as Newest Vms+ User
Aug-18-2023
Product-Related Announcements
Ventripoint Diagnostics Ltd. Announces That Ventripoint and Ascend Cardiovascular, Llc Have Developed A New Integrated Product
Aug-10-2023
Strategic Alliances
Ventripoint Diagnostics Ltd. Announces Collaboration with Ascend Cardiovascular

M&A Advisors
Fasken Martineau DuMoulin LLP


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
Fasken Martineau DuMoulin LLP
Private Placement Advisors
Bloom Burton & Co. Inc., Burstall LLP, D&D Securities Inc., Macquarie Private Wealth Inc., Troutman Pepper Hamilton Sanders LLP
Public Offering Advisors
BDO Canada LLP, Boyle & Co. LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
MarketLine

Sep 30, 2023 06:01 AM
VPT
VentriPoint Diagnostics Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
84
GlobalData

Sep 15, 2023 04:14 AM
VPT
VentriPoint Diagnostics Ltd (VPT.CVE) - Medical Devices Product Pipeline Summary
Reports
65
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 14, 2023 06:00 PM
VPT
Rating Update for VentriPoint Diagnostics Ltd
EPS Estimates*
3
GlobalData

Sep 11, 2023 11:02 PM
VPT
VentriPoint Diagnostics Ltd (VPT.CVE) - Financial Analysis Review
Reports
137
GlobalData

Aug 29, 2023 01:47 AM
VPT
VentriPoint Diagnostics Ltd (VPT.CVE) - Medical Equipment - Deals and Alliances Profile
Reports
42
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 19, 2023 06:00 PM
VPT
Rating Update for VentriPoint Diagnostics Ltd
EPS Estimates*
3
MarketLine

Jun 26, 2023 06:01 AM
VPT
VentriPoint Diagnostics Ltd.
Reports
27
GlobalData

Jun 09, 2023 08:51 AM
VPT
VentriPoint Diagnostics Ltd (VPT.CVE) - Medical Devices Product Pipeline Summary
Reports
62
GlobalData

Jun 09, 2023 03:14 AM
VPT
VentriPoint Diagnostics Ltd (VPT.CVE) - Financial Analysis Review
Reports
134
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
May 29, 2023 06:00 PM
VPT
Rating Update for VentriPoint Diagnostics Ltd
EPS Estimates*
3


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Hodgkinson, Robert 

2,000,000

1.28

0.4

Oct-02-2023


Adams B.A.Sc., ICD.D., M.A.Sc., Ph.D., George 

941,616

0.60

0.2

Oct-02-2023


Hemo Stat Ltd.

100,000

0.06

0.0

Oct-02-2023


Hodgkinson Equities Corporation

0

0.00

0.0

Oct-02-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Adams B.A.Sc., ICD.D., M.A.Sc., Ph.D., George 
941,616
297,541

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Hodgkinson Equities Corporation
0
(2,000,002)
Hodgkinson, Robert 
2,000,000
(1)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Ventripoint Medical System, VMS+ Software


Upcoming Events
Date/Time
Type
Nov-01-2023
Shareholder/Analyst Calls
Nov-01-2023
Annual General Meeting
Nov-30-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Oct-04-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
Management Proxy Materials
632 KB
Oct-04-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
Management Proxy Materials
103 KB
Oct-04-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
Management Proxy Materials
68 KB
Oct-03-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
Material Change Report
530 KB
Oct-03-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
News Releases
497 KB
Sep-28-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
News Releases
145 KB
Sep-15-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
News Releases
132 KB
Sep-13-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
News Releases
131 KB
Sep-08-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
News Releases
131 KB
Aug-31-2023
VentriPoint Diagnostics Ltd. (TSXV:VPT)
SEDAR
Notice of the Meeting and Record Date
313 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Adams B.A.Sc., ICD.D., M.A.Sc., Ph.D., George  (Executive Chairman)
May-06-2021 - May-07-2021
Common Shares
40,000
19,882
Open Market Acquisition
6.62
Exchange Announcement
-
May-06-2021
Common Shares
20,000
10,031
Open Market Acquisition
-
Exchange Announcement
-
May-07-2021
Common Shares
20,000
9,850
Open Market Acquisition
-
Exchange Announcement
Adams B.A.Sc., ICD.D., M.A.Sc., Ph.D., George  (Executive Chairman)
May-04-2021 - May-05-2021
Common Shares
40,000
20,132
Open Market Acquisition
7.09
Exchange Announcement
-
May-04-2021
Common Shares
20,000
9,930
Open Market Acquisition
-
Exchange Announcement
-
May-05-2021
Common Shares
20,000
10,203
Open Market Acquisition
-
Exchange Announcement
Adams B.A.Sc., ICD.D., M.A.Sc., Ph.D., George  (Executive Chairman)
May-04-2021
Common Shares
312,500
172,391
Derivative Exercise and Retained Stock
107.18
Exchange Announcement
Hodgkinson Equities Corporation
Apr-27-2021
Common Shares
300,000
0
Derivative Exercise and Retained Stock
17.65
Exchange Announcement
Hodgkinson Equities Corporation
Apr-27-2021
Common Shares
(311,095)
(205,805)
Open Market Disposition
(13.46)
Exchange Announcement
-
Apr-27-2021
Common Shares
(11,095)
(7,903)
Open Market Disposition
-
Exchange Announcement
-
Apr-27-2021
Common Shares
(300,000)
(197,902)
Open Market Disposition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Adams, George 
Executive Chairman
(519) 803-6937
-
gadams@ventripoint.com
Schwartz, Samuel 
Chair of Business Advisory Committee
(416) 595-2384
-

AuCoin, Randy 
Director
416-848-4156
-

Fitzgerald, Fiona 
Director
416-848-4156
-

Gatzoulis, Michael
Member of Scientific Advisory Board
-
-
-
Hodgkinson, Robert 
Independent Director
416-848-4156
-

Krasuski, Richard
Member of Scientific Advisory Board
-
-
-
Lewin, Mark
Member of Scientific Advisory Board
-
-
-
MacNaught, Hugh 
Independent Director
416-848-4156
-

Sahn, David
Member of Scientific Advisory Board
-
-
-
Skinner, Gregory 
Member of Board of Clinical Advisors
416-848-4156
-

Solomon, Scott D. 
Member of Scientific Advisory Board
416-848-4156
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Adams, George 
Executive Chairman
(519) 803-6937
-
gadams@ventripoint.com
Macanovic, Alvira 
CEO, President and VP of Operations, Regulatory Affairs & Quality Assurance
416-848-4156
-

Jeon, Jimmy 
Chief Financial Officer
416-848-4156
-

Katagiri, Hirotaka 
CTO &  Business Development Division Director
416-848-4156
-

Naman, Jessica 
Director of Marketing
416-848-4156
-
-
Graba, Jim 
Application Specialist & Chief Trainer
416-848-4156
-
-
Hirson, Desmond 
Consultant
416-848-4156
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâ€™S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâ€™s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
